Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA

Table 1 Subject demographics and baseline characteristics (FAS)

Characteristic	Subjects N = 155
Age (years), mean (SD)	53.7 (13.1)
Sex, n (%)
Male	104 (67.1)
Race, n (%)
White	129 (83.2)
Black/African American	4 (2.6)
Other	3 (1.9)
Missing	19 (12.3)
BMI (kg/m²), mean (SD)	27.5 (4.9)
Cause of spasticity, n (%)
Ischemic stroke	87 (56.1)
Hemorrhagic stroke	45 (29.0)
Traumatic brain injury	11 (7.1)
Other cerebral vascular disorders	6 (3.9)
Brain tumor	4 (2.6)
Cerebral palsy	2 (1.3)
Time since diagnosis of event leading to spasticity (months), median (range)
Left body side; n = 81	61.4 (2.8–428.9)
Right body side; n = 68	46.5 (3.7–372.8)
REPAS^a score at study baseline, mean (SD)	24.8 (6.7)
DAS^b score at study baseline, mean (SD)
Principle therapeutic target	2.6 (0.5)
Hygiene	2.6 (0.5)
Dressing	2.6 (0.5)
Limb position	2.6 (0.5)
Pain	2.8 (0.4)

^aREPAS score of the treated body side consisting of the sum scores for 13 items, each rated using the Ashworth Scale from 0 to 4, ranging from 0 (no resistance to passive movement for any of the items) to 52 (limbs rigid to passive movement for all items)
^bDAS score, ranging from 0 (no disability) to 3 (severe disability, normal activities limited)
BMI body mass index, DAS Disability Assessment Scale, FAS full analysis set, REPAS Resistance to Passive Movement Scale, SD standard deviation

ISSN: 1477-7525